REGINA: regorafenib, nivolumab, and SCRT in rectal adenocarcinoma 

Shouki Bazarbashi, MBBS, Alfaisal University & King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, discusses the interim findings of the Phase II REGINA trial (NCT04503694) of regorafenib, nivolumab, and short-course radiotherapy (SCRT) in stage II-III rectal adenocarcinoma. The trial's primary endpoint was a complete response (CR) at one year and the combination therapy met the primary endpoint. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.